tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Ascites D001201 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Whalen HR et al. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime. 2017 Transplantation pmid:26950724
Alloway RR Mounting Clinical Evidence With Tacrolimus Generic Products. 2017 Transplantation pmid:28749820
Ouyang J et al. Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections. 2005 Transplantation pmid:15912108
Haririan A et al. Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. 2003 Transplantation pmid:12717201
Abbott KC et al. New-onset gout after kidney transplantation: incidence, risk factors and implications. 2005 Transplantation pmid:16340779
Villanueva G and Baldwin D Rosiglitazone therapy of posttransplant diabetes mellitus. 2005 Transplantation pmid:16340782
Han DH et al. Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. 2010 Transplantation pmid:20562737
Stegall MD et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. 1997 Transplantation pmid:9422404
Shield CF et al. Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group. 1997 Transplantation pmid:9422413
Ueno P et al. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. 2017 Transplantation pmid:27490418
Demetris AJ et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. 1992 Transplantation pmid:1374944
Tory R et al. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. 2009 Transplantation pmid:19584682
Weiler N et al. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. 2010 Transplantation pmid:21048536
Chisholm MA et al. Renal transplant patient compliance with free immunosuppressive medications. 2000 Transplantation pmid:11063348
Dominguez J et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. 2000 Transplantation pmid:11063349
Busuttil RW et al. General guidelines for the use of tacrolimus in adult liver transplant patients. 1996 Transplantation pmid:8607197
Abu-Qaoud MS et al. Lack of relationship between microvascular and macrovascular disease in heart transplant recipients. 2012 Transplantation pmid:23044666
Nogueira JM et al. A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. 1999 Transplantation pmid:10096529
Hoogduijn MJ et al. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. 2008 Transplantation pmid:19005411
Woodward RS et al. Renal graft survival and calcineurin inhibitor. 2005 Transplantation pmid:16177637
Tzakis AG et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. 2004 Transplantation pmid:15114087
Talbot D et al. Alopecia as a consequence of tacrolimus therapy in renal transplantation? 1997 Transplantation pmid:9415574
Gregory CR et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. 1995 Transplantation pmid:7533955
Kandula P et al. Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients. 2012 Transplantation pmid:23037007
Gill JS et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. 2010 Transplantation pmid:20098280
Wallia A et al. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. 2010 Transplantation pmid:20098286
Pascual J et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. 2009 Transplantation pmid:19136902
Suzuki S et al. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. 1993 Transplantation pmid:7685932
McDiarmid SV et al. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. 1993 Transplantation pmid:7685933
Lauria MW et al. Metabolic long-term follow-up of functioning simultaneous pancreas-kidney transplantation versus pancreas transplantation alone: insights and limitations. 2010 Transplantation pmid:20061923
Pascual M et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. 1998 Transplantation pmid:9869086
Chung BH et al. Suppressive Effect of 1α,25-Dihydroxyvitamin D3 on Th17-Immune Responses in Kidney Transplant Recipients With Tacrolimus-Based Immunosuppression. 2017 Transplantation pmid:28107277
Strumph P et al. The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. 1995 Transplantation pmid:7542815
Baran DA et al. Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. 2002 Transplantation pmid:12438960
Kasahara M et al. Role of HLA compatibility in pediatric living-related liver transplantation. 2002 Transplantation pmid:12438966
Hudnall SD Cardiac hypertrophy postliver transplantation: a role for FK506 and cyclosporine A? 2002 Transplantation pmid:12369583
Gallon LG et al. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. 2007 Transplantation pmid:17519781
Fukushima D et al. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. 2015 Transplantation pmid:24846306
Higgins R et al. Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation. 2009 Transplantation pmid:19300192
Steiner RW Steroid withdrawal in kidney transplantation: the subgroup fallacy. 2011 Transplantation pmid:21336084
Jain AB et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. 2003 Transplantation pmid:14501862
Ciancio G et al. A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. 2013 Transplantation pmid:23903014
Hewitt CW and Black KS Comparative studies of FK506 with cyclosporine. 1988 Transplantation pmid:2458644
de Jonge H et al. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. 2010 Transplantation pmid:20592652
Yuzawa K and Fukao K Topical FK506 ointment for skin grafting. 1998 Transplantation pmid:9565111
Higgins RM et al. Conversion from tacrolimus to cyclosporin in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. 2000 Transplantation pmid:10919600
Puig I Marí JM et al. Reflex sympathetic dystrophy syndrome of the lower limbs in a renal transplant patient treated with tacrolimus. 2000 Transplantation pmid:10919604
Zieliński A et al. Simultaneous pancreas-kidney transplant from living related donor: a single-center experience. 2003 Transplantation pmid:12923442
Erickson LM et al. Microarray-based gene expression profiles of allograft rejection and immunosuppression in the rat heart transplantation model. 2003 Transplantation pmid:12923448
Markus PM et al. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. 1991 Transplantation pmid:1718063